National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Send to Printer
Retinoblastoma Treatment (PDQ®)     
Last Modified: 08/12/2009
Health Professional Version
Changes to This Summary (08/12/2009)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Intraocular Retinoblastoma 1

Added text 2 to state that Group D eyes were at high risk for enucleation when treated with carboplatin, etoposide, and local ophthalmic treatment (cited Lumbroso-Le Rouic et al. as reference 44 and level of evidence 3iiDiii).

Added text 3 about treatment options under clinical investigation (cited Abramson et al. as reference 48 and level of evidence 3iiiDiii).



Table of Links

1http://www.cancer.gov/cancertopics/pdq/treatment/retinoblastoma/HealthProfessio
nal/56.cdr#Section_56
2http://www.cancer.gov/cancertopics/pdq/treatment/retinoblastoma/HealthProfessio
nal/151.cdr#Section_151
3http://www.cancer.gov/cancertopics/pdq/treatment/retinoblastoma/HealthProfessio
nal/228.cdr#Section_228